RxDoctor Payments Data

Abedelrahim Asfour, MD

Cardiovascular Disease · Phoenix, AZNPI 1588609267

Payments from drug & device makers

$3,378in general payments, 2019–2025

Across 66 payments — averaging $51.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$1K
  • Boston Scientific$519
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$449
  • Abbott$428
  • Amgen$284
  • Inspire Medical Systems, Inc.$153
  • plus $507 from 11 others

What the payments were for

  • Travel & lodging$49415%
  • Food & beverage$2,88485%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,378 in reported general payments places this provider in the 55th percentile of 423 cardiovascular disease providers in Arizona.

See all cardiovascular disease providers in Arizona

Medicare billing

Part B allowed, 2024
$80,487
Medicare patients
341
Services billed
910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban338$444,223
EntrestoSacubitril/Valsartan100$139,397
XareltoRivaroxaban108$132,595
Repatha SureclickEvolocumab88$84,763
MultaqDronedarone Hcl29$54,460
BrilintaTicagrelor54$39,033
Praluent PenAlirocumab30$37,250
Metoprolol Succinate381$6,794
Atorvastatin Calcium428$6,534
ClopidogrelClopidogrel Bisulfate356$6,505
Ranolazine ErRanolazine54$5,876
Rosuvastatin Calcium257$3,948
Losartan Potassium194$2,940
Carvedilol191$2,771
Metoprolol Tartrate231$1,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$444,223338 claims
Johnson & JohnsonXarelto$80$132,595108 claims
Sanofi-aventis U.S. LLCMultaq$108$54,46029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 423 cardiovascular disease providers in Arizona.

Other cardiovascular disease in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →